Advertisement

Hydralazin bei chronischer Herzinsuffizienz. Pro und contra

  • W. Rutishauser
Conference paper

Zusammenfassung

Hydralazin und Dihydralazin sind seit den 50er Jahren als direkt an der glatten Gefäßmuskulatur angreifende arterioläre Vasodilatatoren bekannt. Eine Interferenz von Hydralazin mit der sympathischen neuromuskulären Endplatte wird diskutiert [2, 19], so daß eine die baroreflexbedingte Aktivierung des sympathischen Nervensystems überschießende adrenergische Stimulation resultiert [7]. Außerdem haben Spokas et al. [16] gezeigt, daß der Effekt von Hydralazin an der Kaninchenaorta nach Entfernung des Endothels geringer ist. Sie schlossen daraus, daß Hydralazin seine muskelrelaxierende Wirkung auf die Media in niedrigen, klinisch relevanten Dosierungen auch über eine endothelial bedingte Komponente entfaltet.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Alarcon-Segovia D, Wakim HC, Worthington IW, Ward LE (1967) Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine 46: 1–33PubMedCrossRefGoogle Scholar
  2. 2.
    Chevillard C, Mathieu M, Saiag B, Worcel M (1980) Hydralazine: Effect on the outflow of noradrenaline and mechanical responses evoked by sympathetic nerve stimulation of the rat tail artery. Br J Pharmacol 69: 415–420PubMedGoogle Scholar
  3. 3.
    Conradson TB, Ryden L, Ahlmark G, Saetre H, Persson S, Nyquist O, Wemersson B (1984) Clinical efficacy of hydralazine in chronic heart failure: One-year double-blind placebo-controlled study. Am Heart J 108: 1001–1006PubMedCrossRefGoogle Scholar
  4. 4.
    Franciosa JA, Weber KT, Levine TB, Kinasewitz GT, Janicki JS, West J, Henis MMJ, Cohn JN (1982) Hydralazine in the long-term treatment of chronic heart failure: Lack of difference from placebo. Am Heart J 104: 587–594PubMedCrossRefGoogle Scholar
  5. 5.
    Greenberg BH, DeMots H, Murphy E, Rahimtoola R (1980) Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency. Circulation 62: 49–55PubMedGoogle Scholar
  6. 6.
    Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K (1978) Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 58: 273–279PubMedGoogle Scholar
  7. 7.
    Khatri I, Uemura N, Notargiacomo A, Freis E (1977) Direct and reflex cardiostimulatory effects of hydralazine. Am J Cardiol 40: 38–42CrossRefGoogle Scholar
  8. 8.
    Magorien RD, Unverferth DV, Leier CV (1984) Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses. Am J Med 77: 267–274PubMedCrossRefGoogle Scholar
  9. 9.
    Massie B, Ports K, Chatterjee K, Parmley W, Ostland J, Young JD, Haughom F (1981) Longterm vasodilator therapy for heart failure: Clinical response and its relationship to hemodynamic measurements. Circulation 63: 269–278PubMedCrossRefGoogle Scholar
  10. 10.
    Mathey D, Hanrath P, Polster J, Witte G, Montz R, Bleifeld W (1981) Short and long-term effects of hydralazine of left ventricular pump function and renal hemodynamics in chronic congestive heart failure. In: Rutishauser W (ed) The place of vasodilators in the long-term treatment of intractable heart failure. Huber, Bern, pp 23–28Google Scholar
  11. 11.
    Morand P, Masson D, Lavigne G (1981) The long-term effects of dihydralazine in chronic heart failure. In: Rutishauser W (ed) The place of vasodilators in the long-term treatment of intractable heart failure. Huber, Bern, pp 30–40 (and unpublished follow-up)Google Scholar
  12. 12.
    Packer M, Meller J, Medina N, Yushak M, Gorlin R (1982) Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. N Engl J Med 306: 57–62PubMedCrossRefGoogle Scholar
  13. 13.
    Reifart N, Kaltenbach M, Bussmann WD (1984) Loss of effectiveness of dihydralazine in the long-term treatment of chronic heart failure. Europ Heart J 5: 568–580Google Scholar
  14. 14.
    Rouleau JL, Chatterjee K, Benge W, Parmley WW, Hiramatsu B (1982) Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: A comparative study. Circulation 65: 671–678PubMedCrossRefGoogle Scholar
  15. 15.
    Rutishauser W (1983) A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. Europ Heart J 4 (Suppl A): 149–152Google Scholar
  16. 16.
    Spokas EG, Folco G, Quilley J, Chander P, McGiff JC (1983) Endothelial mechanism in the vascular action of hydralazine. Hypertension 5 (Suppl 1): 107–111Google Scholar
  17. 17.
    Walsh WF, Greenberg BH (1981) Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 64: 499–505PubMedCrossRefGoogle Scholar
  18. 18.
    Wilson JR, Hoyt RW, Ferraro N, Janicki JS, Weber KT (1984) Effect of hydralazine on nutritive flow to working canine gracilis skeletal muscle. JACC 4: 529–534PubMedGoogle Scholar
  19. 19.
    Worcel M, Saiag B, Chevillard C (1980) An unexpected mode of action of hydralazine. TIPS 1: 136–138Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • W. Rutishauser
    • 1
  1. 1.Centre de CardiologieHôpital Cantonal UniversitaireGenève 4Switzerland

Personalised recommendations